Vizsla Copper Corp. (VCUFF)

Verve Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 31, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Feb 28, 2021	Feb 29, 2020
Net Income	-13.24	-13.11	-2.25	-2.35	-0.05	-0.22
Depreciation & Amortization	10.32	10.32	-	-	0.03	0.03
Stock-Based Compensation	0.68	0.79	0.74	1.12	-	0.02
Provision & Write-off of Bad Debts	-	-	-	-	-	0.01
Other Operating Activities	-0.98	-1.04	-0.61	-0.34	-0.21	0.1
Change in Accounts Receivable	-	-	-	-	-0.01	0.02
Change in Accounts Payable	-0.42	-0.35	-0.35	0.4	0.01	0.02
Change in Other Net Operating Assets	0.16	0.02	-0.12	-0.09	-0.09	0.03
Operating Cash Flow	-3.48	-3.38	-2.59	-1.26	-0.32	0
Capital Expenditures	-3.93	-3.82	-2.58	-0.32	-1.1	-0.01
Cash Acquisitions	0	0.09	1.71	-0.03	-	-
Other Investing Activities	-	-	-	-	-	0.01
Investing Cash Flow	-3.93	-3.89	-0.87	-0.36	-1.1	0
Long-Term Debt Repaid	-	-0.05	-	-	-0.04	-0.04
Net Debt Issued (Repaid)	-0.05	-0.05	-	-	-0.04	-0.04
Issuance of Common Stock	7.96	8.5	0.05	6.27	3.53	-
Other Financing Activities	-0.53	-0.58	-	-0.08	-	-
Financing Cash Flow	7.39	7.87	0.05	6.19	3.49	-0.04
Net Cash Flow	-0.02	0.61	-3.4	4.57	2.08	-0.03
Free Cash Flow	-7.41	-7.2	-5.16	-1.59	-1.42	-0.01
Free Cash Flow Per Share	-0.04	-0.07	-0.13	-0.10	-0.01	-
Cash Interest Paid	-	-	-	-	0.01	0.01
Levered Free Cash Flow	-1.45	-1.58	-3.9	-	-0.89	-0.06
Unlevered Free Cash Flow	-1.45	-1.58	-3.9	-	-0.88	-0.05
Change in Net Working Capital	-0.31	0.08	0.32	-	-0.3	-0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.